Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial

Documenti analoghi

• First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age
  di: Lindgren, Line M., et al.
  Pubblicazione: (2017)
• Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months
  di: Sáez-Llorens, Xavier, et al.
  Pubblicazione: (2020)
• Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age
  di: Bravo, Lulu C., et al.
  Pubblicazione: (2020)
• Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
  di: Dietrich, Jes, et al.
  Pubblicazione: (2014)
• Safeguarding vaccine production and supply strategies for polio eradication endgame
  di: Bandyopadhyay, Ananda S., et al.
  Pubblicazione: (2021)